Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer

J Thorac Dis. 2018 Nov;10(Suppl 33):S4082-S4084. doi: 10.21037/jtd.2018.09.103.

Authors

Minoru Fukuda^{1

2}, Hiroyuki Yamaguchi², Hiroshi Mukae², Kazuto Ashizawa^{1

3}

Affiliations

¹ Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
² Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
³ Department of Clinical Oncology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

No abstract available

Publication types

Editorial
Comment